CTT1057

DRUG3 trials

Sponsors

Cancer Targeted Technology

Conditions

Prostate CancerRenal Cell Carcinoma

Phase 1

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

CompletedNCT02916537

Cancer Targeted TechnologyProstate Cancer

Start: 2016-09-30End: 2017-08-28Updated: 2017-11-06

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

CompletedNCT03427476

Cancer Targeted TechnologyRenal Cell Carcinoma

Start: 2018-01-01End: 2018-08-31Updated: 2019-04-22

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

CompletedNCT03822871

Cancer Targeted TechnologyProstate Cancer

Start: 2019-04-01End: 2023-02-08Updated: 2024-03-21

Related Papers

First-in-human phase 1 PET study of CTT1057, a novel <sup>18</sup>F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer.

Journal of Clinical Oncology2017-05-202 citations